X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to exclusively discover two targeted protein degraders against critical oncogenic proteins that C4T has progressed within its internal discovery pipeline using its proprietary TORPEDO® platform.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: $756.0 million Upfront Cash: $16.0 million
Deal Type: Collaboration March 04, 2024
Details:
The proceeds will be used to develop and commercialize CFT8919, an orally bioavailable BiDAC™ degrader designed to be potent and selective against EGFR L858R for non-small cell lung cancer patients, in Greater China.
Lead Product(s): CFT8919
Therapeutic Area: Oncology Product Name: CFT8919
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Betta Pharmaceuticals
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Financing January 04, 2024
Details:
Under the agreement, Merck will develop degrader-antibody conjugates (DACs), an emerging modality designed to selectively target and neutralize disease-causing proteins in cancer cells.
Lead Product(s): Degrader-antibody Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $610.0 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement December 12, 2023
Details:
CFT7455 is an orally bioavailable MonoDAC degrader designed to be highly potent and selective against its intended targets of IKZF1 and IKZF3 and overcome shortcomings of currently approved therapies to treat multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL).
Lead Product(s): CFT7455,Dexamethasone
Therapeutic Area: Oncology Product Name: CFT7455
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
CFT8919 is an orally bioavailable allosteric BiDAC™ degrader that is designed to be potent and selective against EGFR bearing an oncogenic L858R mutation. In preclinical studies, CFT8919 is active in in vitro and in vivo models of L858R driven non-small cell lung cancer.
Lead Product(s): CFT8919
Therapeutic Area: Oncology Product Name: CFT8919
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2023
Details:
Under the terms of the agreement, Betta Pharmaceuticals will develop and commercialize CFT8919, an orally bioavailable BiDAC™ degrader designed to be potent and selective against EGFR L858R for non-small cell lung cancer patients, in Greater China.
Lead Product(s): CFT8919
Therapeutic Area: Oncology Product Name: CFT8919
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Betta Pharmaceuticals
Deal Size: $392 million Upfront Cash: $10 million
Deal Type: Licensing Agreement May 30, 2023
Details:
CFT1946 is an orally bioavailable BiDAC™ degrader designed to be potent and selective against BRAF V600 mutant targets. C4T is advancing CFT1946 to the clinic to study treatment for BRAF V600 mutant solid tumors including NSCLC, colorectal cancer, and melanoma.
Lead Product(s): CFT1946,Trametinib
Therapeutic Area: Oncology Product Name: CFT1946
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2023
Details:
In pre-clinical studies, CFT1946 is active in vivo and in vitro in models with BRAF-V600E-driven disease and in the escape mutant BRAF models. C4T is advancing CFT1946 to the clinic to study treatment for BRAF-V600 mutant solid tumors including lung, colorectal or melanoma.
Lead Product(s): CFT1946
Therapeutic Area: Oncology Product Name: CFT1946
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2022
Details:
CFT8634 is a BiDAC™ degrader targeting BRD9 for the treatment of cancers that are dependent on BRD9, including synovial sarcoma and SMARCB1-null cancers.
Lead Product(s): CFT8634
Therapeutic Area: Oncology Product Name: CFT8634
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Details:
Single agent CFT7455 induces deep and durable degradation of IKZF1/3 and meaningful decreases in serum-free light chain at doses lower than expected based on pre-clinical studies.
Lead Product(s): CFT7455,Dexamethasone
Therapeutic Area: Oncology Product Name: CFT7455
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
